* GeneDx Holdings Corp WGS.OQ WGS.O is expected to show
a rise
in quarterly revenue when it reports results on April 29 for
the period ending March 31 2024
* The Stamford Connecticut-based company is expected to
report a
14.7% increase in revenue to $49.463 million from $43.14 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for GeneDx Holdings Corp is
for a
loss of 67 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for GeneDx
Holdings
Corp is $12.50, above its last closing price of $11.17.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.64 -0.75 -0.69 Beat 8.4
Sep. 30 2023 -1.28 -1.31 -0.82 Beat 37.4
Jun. 30 2023 -1.41 -1.31 -1.64 Missed -24.9
Mar. 31 2023 -1.36 -2.14 -2.44 Missed -14.2
Dec. -4.84 -5.28 -8.25 Missed -56.2
31 2022
Sep. 30 2022 -6.91 -7.01 -6.60 Beat 5.9
Jun. 30 2022 -6.61 -6.93 -8.25 Missed -19
Mar. 31 2022 -10.54 -10.19 -10.23 Missed -0.4
This summary was machine generated April 26 at 22:13 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)